Bevacizumab dosing guidelines take various factors into account, such as the type of cancer being treated and the kind of chemotherapy that is also being used, among other things. For example, when treating non-squamous, non-small cell lung cancer, the recommend dose is 15 mg per kg every three weeks. For colorectal cancer, bevacizumab dosing guidelines call for 5 or 10 mg per kg every 14 days.
In late 2010, the United States Food and Drug Administration (FDA) recommended that bevacizumab's breast cancer approval be removed. Studies have not shown the drug to increase survival in people with breast cancer, and there is not sufficient benefit to outweigh the risks.
This action does not affect bevacizumab's approval for other uses. Healthcare providers may still use bevacizumab to treat breast cancer, although they will be doing so in an "off-label" fashion.
An Introduction to Bevacizumab DosingThe dose of bevacizumab (Avastin®) that your healthcare provider recommends will vary depending on a number of factors, including:
- Your weight
- Whether you have colon, rectal, or lung cancer
- The type of chemotherapy you are receiving
- Other medications you may be taking
- Other medical conditions you may have.
As is always the case, do not adjust your bevacizumab dose unless your healthcare provider specifically instructs you to do so.
Bevacizumab Dosing for Colorectal CancerThe recommended dose of bevacizumab when treating colon or rectal cancer is either 5 mg or 10 mg per kg (about 2.3 mg to 4.5 mg per pound) given by IV every 14 days. The recommended dose will vary (either 5 or 10 mg per kg) based on the type of chemotherapy you are receiving along with bevacizumab.